

# Shinji Atagi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8079716/publications.pdf>

Version: 2024-02-01

9  
papers

391  
citations

1307366

7  
h-index

1474057

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

609  
citing authors

| # | ARTICLE   | IF  | CITATIONS |
|---|---|-----|-----------|
| 1 | Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). <i>Lancet Oncology</i> , The, 2012, 13, 671-678. | 5.1 | 213       |
| 2 | Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.  | 5.8 | 69        |
| 3 | Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. <i>Cancer Medicine</i> , 2020, 9, 6597-6608.  | 1.3 | 30        |
| 4 | Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). <i>Clinical Lung Cancer</i> , 2018, 19, e619-e627.   | 1.1 | 23        |
| 5 | A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. <i>Lung Cancer</i> , 2018, 125, 93-99.  | 0.9 | 21        |
| 6 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.   | 3.2 | 14        |
| 7 | Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. <i>The Lancet Healthy Longevity</i> , 2021, 2, e791-e800.   | 2.0 | 10        |
| 8 | A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2018, 19, e711-e715.   | 1.1 | 9         |
| 9 | Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study. <i>Lung Cancer</i> , 2022, 165, 152-163.   | 0.9 | 2         |